Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership with Mirxes Singapore. Together, they will utilize their combined technological and operational strengths to offer solid tumor origin identification testing services to medical practitioners and patients in Singapore, Malaysia, Thailand, Indonesia, and the Philippines.
Collaboration Details and Technology Exchange
Under the terms of the partnership, Canhelp Genomics will provide Mirxes with its advanced Gene Expression Test System for Human Tumor Origin Identification (Canhelp-Origin). Mirxes will use this technology to establish and deliver tumor origin identification testing services for metastatic cancer patients, utilizing solid tumor tissue slides. The testing operations will be conducted by M Diagnostics, a wholly-owned subsidiary laboratory of Mirxes in Singapore.
Canhelp-Origin: Innovation in Tumor Detection
Canhelp-Origin, based on quantitative RT-PCR technology, is capable of simultaneously detecting the expression patterns of 90 tumor characteristic genes. Coupled with artificial intelligence algorithms, it automatically identifies the type and origin of tumors. This multi-gene expression assay is the first and only tumor origin identification test approved by both China’s National Medical Products Administration (NMPA) and CE in Europe. It has shown exceptional performance in identifying primary lesions in metastatic and poorly differentiated tumors, with the ability to distinguish over 95% of tumor types worldwide with an accuracy rate exceeding 90%.-Fineline Info & Tech
Leave a Reply